



Proteomics International

LABORATORIES LTD

ASX Release
16 October 2020

ASX code: PIQ

First distribution agreement for easy-to-use immunoassay version of PromarkerD test

- **World's first predictive test for diabetic kidney disease to be made available in Italy in partnership with innovative Italian distributor Medical Horizons SRL**
- **Licence marks the first distribution agreement for the easy-to-use, high volume immunoassay version of the PromarkerD test**
- **Agreement is for two years, and will see Medical Horizons become the exclusive distributors for PromarkerD in Italy**
- **Italian Key Opinion Leaders already engaged to help drive early adoption of the test by major hospitals**
- **Italy is home to 3.7 million people with diabetes, with 60 million diabetics across the EU**
- **The launch of PromarkerD immunoassay in Italy to drive demand for the test in other jurisdictions - licensing discussions ongoing in multiple countries**

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) has signed a distribution licensing agreement for the immunoassay version of the PromarkerD predictive test for diabetic kidney disease. The agreement with leading medical distributor Medical Horizons SRL will see the blood test made available to patients in Italy, where 1 in 12 adults has diabetes.

Proteomics International managing director Dr Richard Lipscombe said the partnership marked the first distribution licensing deal for the immunoassay version of the PromarkerD test, PromarkerD (IA). *"Previously we focused on the more sophisticated mass spectrometry test, but the release of this easy-to-use, higher throughput immunoassay platform opens up many more market opportunities,"* he said.

"The availability of the CE Marked PromarkerD immunoassay kit allows new licensing models for this ground-breaking test. We can enter into more traditional distribution agreements with proven companies like Medical Horizons."

The immunoassay (ELISA) technology is cost-effective and standard to clinical diagnostics laboratories around the world. The format allows hundreds of blood samples to be analysed quickly as part of a panel of routine blood tests.

The distribution agreement with Medical Horizons is for two years, exclusive to Italy, and exclusive to PromarkerD (IA). Proteomics International will receive payment for each kit sold. Further details of the licence agreement are commercially sensitive and remain confidential. As for any novel test, market penetration cannot be predicted accurately, hence for the new licence it is not possible to quantify the financial impact on Proteomics International in any given timeframe.

Italy is home to 3.7 million people with diabetes according to the International Diabetes Federation. Across Europe, there are 60 million people with diabetes, and the number is expected to rise to 68 million by 2045 without immediate action. Currently one-in-three people with diabetes develop

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

chronic kidney disease and PromarkerD is the only test available in the European Union for predicting the onset of the condition.

Medical Horizons CEO Guido Osto said bringing PromarkerD to patients in Italy will support clinical decision-making. *“With this technology used as an annual test, doctors will be able to identify at-risk patients for early intervention,”* he said. *“It will help minimise the effects of diabetic kidney disease, and potentially save the healthcare system billions of Euros.”*

Medical Horizons will now complete registration of PromarkerD with the Italian Ministry of Health (one month) at which point the test can start being sold. Medical Horizons are already engaged with a number of Italian Key Opinion Leaders for the promotion and early adoption of the test by major hospitals. The engagement with these KOLs will also help drive awareness and understanding of PromarkerD’s benefits in additional markets [ASX: 12 Oct].

Dr Lipscombe said Proteomics International was currently renegotiating deals with the Company’s existing PromarkerD partners, allowing them to access the immunoassay version of the test. *“We also expect that bringing PromarkerD to Italy will drive demand for the test in other jurisdictions, and we’re continuing discussions with diagnostic and pharmaceutical companies in multiple countries.”*

Authorised by the Board Proteomics International Laboratories Ltd (ASX:PIQ).

ENDS

About PromarkerD (www.PromarkerD.com)

PromarkerD is a predictive test for the early detection of chronic kidney disease (CKD) in patients with type-2 diabetes. CKD is one of the major complications arising from diabetes and if unchecked can lead to dialysis or kidney transplant.

The patented PromarkerD test system uses a simple blood test to detect a unique ‘fingerprint’ of the early onset of disease by measuring three serum proteins (ApoA4, CD5L and IGFBP3), combined with three routinely available conventional clinical variables (age, high-density lipoprotein (HDL)-cholesterol and estimated glomerular filtration rate (eGFR)).

In clinical studies published in leading journals PromarkerD correctly predicted 86% of otherwise healthy diabetics who went on to develop chronic kidney disease within four years. The PromarkerD immunoassay, the PromarkerD mass spectrometry assay, and the PromarkerD software hub have each achieved CE Mark registration in the European Union.

Further information is available through the PromarkerD web portal.

To visit the PromarkerD ADA virtual booth please see: www.PromarkerD.com/product

About Medical Horizons (www.medicalhorizons.it)

Medical Horizons was created to identify medical innovation worldwide that has the potential to become innovative new products, and then develop their commercialisation through a selected Italian sales network. The Company’s existing products cover a number of cancers, women’s health and new-born screening. Medical Horizons is one of the most trusted players in the medical import field in Italy, and its expertise includes understanding the commercial interest that innovative devices will have for the Italian market to ensure products will meet the needs of prospective users .

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

the structure and function of proteins. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities located on Perth's QEII Medical Campus.

Proteomics International's business model is centred on the commercialisation of the Company's world-leading test for diabetic kidney disease, PromarkerD. The Company offsets the cash burn from R&D and product development through provision of specialist analytical services, whilst using its proprietary Promarker™ technology platform to create a pipeline of novel diagnostic tests.

For further information please contact:

Dr Richard Lipscombe

Managing Director

T: +61 8 9389 1992

E: enquiries@proteomicsinternational.com

Dirk van Dissel

Corporate Advisor & Investor Relations

T: +61 408 326 367

E: dirk@candouradvisory.com.au